A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study

Journal of the American College of Cardiology

Volumn 33, Issue 5, 1999, Pages 1347-1352

  Ma, Jing ^a,b   Hennekens, Charles H ^b,e   Ridker, Paul M ^c,d   Stampfer, Meir J ^a,b  

^a Channing Laboratory ^*  (United States)

^b CHANNING LABORATORY   (United States)

^c Division of Preventive Medicine   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY RISK; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES;

EID: 0033117117     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00007-8     Document Type: Article

References (28)

1. Ernst E. The role of fibrinogen as a cardiovascular risk factor. Atherosclerosis 1993;100:1-12.
2. Lowe GOD. Blood rheology in arterial disease. Clin Sci 1985;68:419-25.
3. Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 1986;15:355-70.
4. Eber B, Schumacher M. Fibrinogen: its role in the hemostatic regulation in atherosclerosis. Semin Thromb Hemost 1993;19:104-7.
5. Folsom AR, Wu KK, Conlan MG. Fibrinogen and cardiovascular risk in the Atherosclerosis Risk in Communities (ARIC) Study. In: Ernst E, Koenig W, Lowe GDO, Meade TW, editors. Fibrinogen: A "New" Cardiovascular Risk Factor. Vienna, Austria: Blackwell-MZV, 1992:124-9.
6. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
7. Meade TW, Vickers MV, Thompson SG, Stirling V, Haines AP, Miller GJ. Epidemiological characteristics of platelet aggregability. Br Med J 1985;290:428-32.
8. Meade TW, Vickers MV, Thompson SG, Seghatchian MJ. The effect of physiological levels of fibrinogen on platelet aggregation. Thromb Res 1985;38:527-32.
9. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258:1183-6.
10. Niort G, Bulgarelli A, Cassader M, Pagano G. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988;71:113-9.
11. Bachet P, Lancrenon S, Chassoux G. Fibrinogen and pentoxifylline. Thromb Res 1989;55:161-3.
12. Tohgi H, Takahashi H, Kashiwaya M, Watanabe K. Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin. Stroke 1994;25:2017-21.
13. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35.
14. IHD Registers: Report of the Fifth Working Group. Copenhagen: World Health Organization, 1971.
15. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-46.
16. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
17. SAS/STATR User's Guide Version 6, Fourth Edition, Volume 2. Cary, NC: SAS Institute Inc., 1989:846.
18. Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Münster Heart Study (PROCAM). Isr J Med Sci 1996;32:364-70.
19. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
20. Yarnell JWG, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991;83:836-44.
21. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5.
22. Meade TW, Mellows S, Brozovic M, Miller GJ. Haemostatic function and ischemic heart disease: principal results of the Northwick Heart Study. Lancet 1986;2:533-7.
23. Stone MC, Thorp JM. Plasma fibrinogen - a major coronary risk factor. J R Coll Gen Pract 1985;35:565-9.
24. Balleisen L, Schulte H, Assmann G, Epping PH, van de Loo J. Coagulation factors and the progress of coronary heart disease (letter). Lancet 1987;2:461.
25. Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Study. J Clin Epidemiol 1990;43:913-9.
26. Danesh J, Colins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 1998;279:1477-82.
27. Toss H, Lindahl B, Siegbahn A, Wallentin L, for the FRISC Study Group. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997;96:4202-10.
28. Yarnell JWG, Sweetnam PM, Rogers S, et al. Some long term effects of smoking on the haemostatic system: a report from the Caerphilly and Speedwell Collaborative Surveys. J Clin Pathol 1987;40:909-13.